Business Strategy
Five Forces: George Brown
The pharmaceutical industry is profitable. BMS had about $50 billion in revenue for the 2022 year. The pharmaceutical industry from 2001 to 2022 has grown exponentially year over year, revenue went from $390.2b to $1,482b. “For 2022, the total global pharmaceutical market was estimated at 1.48 trillion U.S. dollars.” (Mikulic) BMS offers innovative solutions to their customers, providing much needed medication to a high demand within society. Research and development remains prominent at BMS to help find the next lifesaving medicine. “In 2022, research and development spending in the pharmaceutical industry totaled some 244 billion U.S. dollars globally.” (Mikulic) Millions of people rely heavily on BMS’s products year over year, helping to keep demand high in the pharmaceutical industry. While BMS has large competitors, each company has a specific area of expertise used to focus their efforts on their target market. They currently provide medicine for cancers, diabetes, arthritis, and more. Research and development is an important piece to remain competitive within an industry. Developing better products and being early to an industry shift will help keep the company profitable for the foreseeable future.
Competitive Strategy: Nick Francisco
BMS focuses on the Industry wide Differentiation strategy, striving to create unique and innovative pharmaceutical products that distinguish itself within the pharmaceutical market and maintain a competitive edge. The competitive strategy for Bristol Myers Squibb is in a very solid and lucrative spot considering the practice areas that the company focuses on. BMS focuses on specific markets, such as chronic and severe illnesses. They can use this to their advantage, as they have resources available to make a continued and sustained effort into developing medicine that is beneficial to the consumer and practice area. BMS dedicates a substantial portion of their efforts to R&D in product development for this area of the market.
To take into consideration
the five forces listed above, BMS has to be diligent in maintaining different
aspects of their strategies in order to keep and maintain their competitive
advantage.
- To deter the competition that
exists in this industry between their competitors, BMS needs to ensure
that their efforts are sustained in making reliable and reputable products
for usage in the treatment of severe illnesses, such as cancer. If BMS can
maintain solid product development, they can keep competition from taking
market share for these types of products.
- Considering the threat of new
entrants, it isn’t really a huge worry for Bristol Meyers Squibb.
BMS has such a long history and reputation available that makes it
extremely difficult for others to enter their type of markets.
Additionally, BMS has a lot of resources and finances available to
pressure new entrants.
- The bargaining power of suppliers
is something that BMS must be cognizant of, however given how much BMS
likely spends on suppliers for resources in product development, it would
be unwise for suppliers to lose them as a client and force BMS to use
somebody else. In most instances, I would not find this to be a huge
issue.
- In reference to the buyers of
their products, they are also not a threat to the company. The
reason for this is that BMS has such a substantial and specified market
for their products, the buyers will not have many options available to
pick otherwise. Moreover, products that are proven to be effective
will be used in an instance where severe illness is the scenario.
- The threat of substitutes is also
minimal, and likely a non-factor - much to the reason that the buyers
don’t have a lot of options. This goes hand in hand with the buyer
bargaining power.
Bristol Myers Squibb
ultimately maintains a competitive advantage based on their confidence in their
research and development, which maintains the reliability of their long-term
products in addition to their manufacturing and testing of new and potentially
better products in the near-term.
Company Value Chain: Karla Rodriguez
During
the planning process, it's important to identify potential sources of
competitive advantage for Bristol-Myers Squibb. By conducting a Value Chain
Analysis, the company's various activities can be examined to determine which
ones may be considered as economic rent sources and which ones could serve as
barriers to new entrants or cause cost disadvantages to competitors. This
analysis allows for a deeper understanding of the company's operations and
potential advantages over its competitors.
Business Processes: Caitlin Monaghan
Customer service is an
integral business process of Bristol Myers Squibb. Customer service at BMS
involves structured processes that follow predefined guidelines and protocols
to handle inquiries, complaints, and requests. The company offers support systems
to healthcare providers, pharmacists, and patients, providing guidance,
information, and assistance regarding their products. BMS offers customer
service through various communication channels, including phone support, email
correspondence, and through digital platforms. This dedication to customer
service ensures that patients receive the necessary support, building trust and
improving the overall healthcare experience.
A dynamic process at
Bristol Myers Squibb is its recruiting process. The pharmaceutical industry
experiences constant changes, and BMS's recruiting efforts dynamically adjust
to these trends. BMS actively engages with potential candidates through social media
platforms, industry events, and networking opportunities to build relationships
with candidates and stay connected with potential talent. The company adapts
its hiring strategies in response to changing business demands. For instance,
they scale up hiring efforts in certain areas due to new drug developments or
market expansion.
Information Systems: Kiran Kaur
Given Bristol Myers
Squibb's differentiation strategy of targeting specific market segments with
superior medications, investing in research and development in areas like
oncology, immunology, and cardiovascular diseases, and staying ahead of
competitors and new entrants through heavy investment in research, their
information systems play a critical role in supporting these strategies. Under
the guidance of Catherine Francisco, we uncovered that BMS utilizes management
information systems such as Salesforce and LinkedIn.
BMS utilizes a variety of
social media platforms to support its marketing and sales, such as Facebook,
Instagram, and LinkedIn. The company uses LinkedIn for talent sourcing and
recruitment. BMS establishes and nurtures talent groups on LinkedIn, connecting
with professionals interested in the company and its industry. These
communities serve as platforms for sharing information, networking, and
fostering relationships with potential candidates.
Bristol Myers Squibb
utilizes Salesforce for customer service to enhance interactions and
relationships with healthcare professionals, patients, and other stakeholders
in the pharmaceutical industry. Salesforce provides a unified platform where
BMS can gather and manage comprehensive customer data. This helps in creating a
complete view of each customer, allowing representatives to personalize
interactions and provide tailored support.
Each of these information
systems support Bristol Myers Squibb's differentiation strategy by focusing on
customer engagement, relationship building, and innovation. These systems
collectively contribute to BMS's efforts to offer superior and targeted medications
in specific therapeutic areas, setting them apart from competitors.